Age-related macular degeneration Medical Services in China

Age-related macular degeneration (AMD) is a progressive, chronic eye disease affecting the macula—the central part of the retina responsible for sharp, detailed vision. It primarily occurs in individuals over 50 and is the leading cause of irreversible central vision loss in older adults worldwide. AMD manifests in two forms: dry (atrophic), accounting for ~90% of cases and characterized by drusen accumulation and gradual photoreceptor degeneration; and wet (neovascular), involving abnormal blood vessel growth, leakage, and rapid vision deterioration if untreated. Risk factors include age, genetics (e.g., CFH and ARMS2 variants), smoking, cardiovascular disease, and diet. Early detection via optical coherence tomography (OCT), fundus autofluorescence, and fluorescein angiography is critical. While no cure exists for dry AMD, antioxidant supplementation (AREDS2 formula) may slow progression; wet AMD is effectively managed with intravitreal anti-VEGF injections (e.g., ranibizumab, aflibercept, conbercept), photodynamic therapy, or newer sustained-release implants.

China offers compelling advantages for AMD treatment: world-class ophthalmology centers—such as Zhongshan Ophthalmic Center (Sun Yat-sen University) and Beijing Tongren Hospital—combine cutting-edge imaging, standardized anti-VEGF protocols, and cost-effective care (up to 40–60% lower than Western countries). Chinese clinicians have pioneered innovations like conbercept—a domestically developed anti-VEGF agent approved by NMPA and WHO prequalified—and demonstrated non-inferior efficacy to ranibizumab in large-scale RCTs (e.g., PHOENIX study). Over 2 million AMD patients have received treatment annually in China, with >92% achieving stable or improved visual acuity after one year of regimen adherence.

China offers compelling advantages for treating age-related macular degeneration (AMD). Its leading ophthalmic centers deploy cutting-edge technologies—including FDA- and CE-approved anti-VEGF agents, advanced OCT angiography, and AI-powered disease progression monitoring—complemented by state-of-the-art surgical suites and ultra-precise intravitreal injection systems. Chinese retinal specialists perform thousands of AMD interventions annually, accumulating deep clinical experience across all stages, especially in managing geographic atrophy and neovascular AMD with personalized regimens. Treatment is highly cost-effective: a full course of anti-VEGF therapy costs 40–60% less than in the US or Western Europe, without compromising quality—many hospitals are ISO-certified and adhere to international protocols. Logistically, medical tourism is streamlined: patients benefit from expedited appointment scheduling (often within 3–5 business days), multilingual coordinators, visa facilitation support, and integrated services including airport transfers, accommodation near hospitals, and post-treatment follow-up via secure telemedicine. Most major cities—Beijing, Shanghai, Guangzhou, and Shenzhen—host JCI-accredited eye hospitals with English-speaking staff and digital health records compatible with overseas providers. This combination of clinical excellence, affordability, and patient-centric coordination makes China a trusted destination for AMD care.

International patients seeking treatment for age-related macular degeneration (AMD) follow a streamlined, patient-centered process. First, submit medical records—including OCT scans, fundus photos, visual acuity tests, and ophthalmologist reports—via secure online portal (3–5 business days for review). Our multilingual care coordinators then schedule a virtual consultation with a retina specialist to assess suitability for anti-VEGF injections, photodynamic therapy, or emerging options like complement inhibitors. Upon approval, we assist with visa support, travel logistics, and accommodation near the clinic. Pre-arrival, patients receive a personalized timeline: baseline diagnostics (Day 1), treatment initiation (Day 2–3), and follow-up monitoring (Days 5–7). Total stay typically ranges from 7–10 days, depending on treatment protocol and response. All consultations, consent forms, and discharge instructions are provided in English; translation services for 12+ languages are available upon request. Dedicated international patient coordinators offer 24/7 support—from airport pickup to medication guidance and post-treatment telehealth follow-ups. We also help coordinate remote monitoring with local ophthalmologists post-return. Required documents include passport copy, recent AMD-related imaging and reports (within 6 months), insurance pre-authorization (if applicable), and completed health questionnaire. Early submission of materials ensures faster scheduling and optimal care continuity.

For patients seeking treatment for Age-Related Macular Degeneration (AMD) in China, a valid passport and Chinese Medical Treatment Visa (Q2 or S2) are required—apply through the nearest Chinese embassy with an official invitation letter from your designated hospital. Travel insurance covering medical emergencies and repatriation is mandatory; most Chinese hospitals accept international credit cards, wire transfers, or third-party medical payment platforms, though cash payments in RMB are also accepted. Pre-arranged accommodation options—including nearby serviced apartments or hospital-affiliated guest houses—are available, often with bilingual support; accompanying family members may stay with you, and translation services can be arranged upon request. Post-treatment, patients receive personalized follow-up care: remote consultations via secure telemedicine platforms, digital access to medical records, and coordinated referrals for local ophthalmologic monitoring abroad. Many top-tier ophthalmology centers in Beijing, Shanghai, and Guangzhou offer AMD-specific protocols—including anti-VEGF injections, photodynamic therapy, and low-vision rehabilitation—delivered by specialists trained in both Western and integrative approaches. All treatment plans comply with China’s National Health Commission standards and are tailored to disease stage and visual function. Please contact your chosen hospital at least four weeks prior to travel to finalize documentation, scheduling, and logistics support.